Related Experiment Video
Updated: Aug 1, 2026

Murine Oropharyngeal Aspiration Model of Ventilator-associated and Hospital-acquired Bacterial Pneumonia
Published on: June 28, 2018
Infection Biomarkers in Children with Chemotherapy-Induced Severe Neutropenia
Wioletta Bal1,2, Zuzanna Piasecka1,2, Klaudia Szuler1
1Department of Pediatrics, Faculty of Medicine, University of Rzeszow, 35-310 Rzeszow, Poland.
Insights
New biomarkers like presepsin and procalcitonin (PCT) improve early infection detection in pediatric febrile neutropenia. These markers aid in risk stratification, enhancing treatment decisions for children undergoing chemotherapy.
Area of Science:
- Pediatric Oncology
- Infectious Diseases
- Biomarker Discovery
Background:
- Febrile neutropenia is a critical complication in pediatric cancer patients undergoing chemotherapy, leading to profound immunosuppression.
- Early and accurate diagnosis of infections in this vulnerable population is a significant clinical challenge.
- This review focuses on the diagnostic and prognostic value of infection biomarkers in children with chemotherapy-induced severe neutropenia.
Purpose of the Study:
- To evaluate the diagnostic and prognostic utility of various infection biomarkers in pediatric febrile neutropenia.
- To assess the performance of established and emerging biomarkers in identifying infections and stratifying risk in immunocompromised children.
Main Methods:
- Systematic review of clinical studies assessing inflammatory biomarkers (CRP, PCT, IL-6, IL-8, IL-10, etc.) in pediatric febrile neutropenia.
- Analysis of diagnostic performance metrics including sensitivity, specificity, and predictive values.
- Inclusion of data on clinical applications and emerging biomarkers like presepsin, MR-proADM, and PSP.
Main Results:
- C-reactive protein (CRP) is nonspecific; procalcitonin (PCT) shows high negative predictive value for bacterial infections.
- Interleukins (IL-6, IL-10) demonstrate strong early diagnostic accuracy (AUC > 0.80) and predict septic shock.
- Emerging biomarkers (presepsin, MR-proADM, PSP) show promising performance, with presepsin achieving near-perfect accuracy in some studies.
Conclusions:
- Biomarkers like PCT, IL-6, IL-8, and IL-10 are valuable for early infection detection and risk stratification in pediatric febrile neutropenia.
- Emerging markers (presepsin, MR-proADM, PSP) enhance diagnostic precision and early sepsis identification.
- Multimarker strategies incorporating novel biomarkers show potential for improved diagnostic performance, requiring further validation.
Background/Objectives:
Febrile neutropenia is a frequent and potentially life-threatening complication in pediatric oncology patients receiving chemotherapy. Due to profound immunosuppression, early diagnosis of infections remains a major clinical challenge. This review evaluates the diagnostic and prognostic utility of infection biomarkers in children with chemotherapy-induced severe neutropenia.
Methods:
We reviewed clinical studies that assessed the diagnostic performance of inflammatory biomarkers-including C-reactive protein (CRP), procalcitonin (PCT), interleukins (IL-6, IL-8, IL-10), and others-in pediatric febrile neutropenia. The review includes data on sensitivity, specificity, predictive value, and clinical applications.
Results:
CRP remains a common but nonspecific marker, often insufficient for early stratification. PCT showed consistently high negative predictive value and early responsiveness to bacterial infections. IL-6 and IL-10 demonstrated strong early diagnostic accuracy in the early phase (AUC > 0.80 in multiple studies) and were particularly useful in predicting septic shock when combined. IL-8, while less specific, may help rule out infection when levels are low. Emerging biomarkers such as presepsin, MR-proADM, and PSP showed promising diagnostic performance. Presepsin achieved near-perfect accuracy in some cohorts (AUC up to 0.996), outperforming CRP and PCT, though its ability to discriminate bacteremia at fever onset varied. MR-proADM demonstrated consistent AUCs above 0.75 and may support early sepsis identification. PSP was associated with significantly elevated levels in sepsis. Additional novel markers-including sTNFR-II, sIL-2R, IP-10, Flt-3L, MCP-1-a, and MBL-showed encouraging diagnostic profiles in individual studies, particularly due to high specificity, but require external validation. G-CSF also emerged as a promising candidate in multimarker models. In contrast, TNF-α and IL-1β displayed limited utility as standalone indicators.
Conclusions:
Biomarkers such as PCT, IL-6, Il-8, and IL-10 offer valuable tools for early infection detection and risk stratification in pediatric febrile neutropenia. Emerging markers-including presepsin, MR-proADM, and PSP-further enhance diagnostic precision and may support early identification of sepsis. Multimarker strategies, particularly those incorporating presepsin, IL-10, or MR-proADM, show potential to improve diagnostic performance beyond conventional markers. Further prospective validation is needed to optimize clinical implementation and guide personalized treatment decisions.
Related Concept Videos
Rocky Mountain Spotted Fever
Antiprotozoal Agents

